Member Info for countingcards

DXB1 it may have been removed and like you I unfiltered for a moment and then back on so not sure what comments are being referred.

The constant ups and downs over the last two years within a price range is going to catch a lot of sellers off guard one day, and I believe that day/hour is close.

https://meetings.asco.org/abstracts-presentations/250674

Comedy gold LOL

Well if it keeps rising then I can see divorce proceedings on the way.

Nice find Greend100. As this was 1pm ET time was this not worthy of an RNS or was this exclusive to Cizbio.inc. Maybe an update tomorrow?

TT

In light of today's RNS would you kindly explain with your vast knowledge the following please:

"I did wonder where Fraser Lang has been given mates rates for a quick turnover of profit. (There is a large gap in the chart at 1.6p which will inevitably be filled)" This was from your last post.

You are slowly beginning to realise a truth about yourself.

Its been interesting to see the last six days trading where there has been consistent small buys and hardly any selling. Then the news this morning of a CLN with an established holder who wants no interest on the CLN but also makes a positive comment on the agreement. Whats not to like? The trend has for now turned positive again.

According to Reuters, cuts across US federal health agencies exacerbated concerns in the biotech sector, already facing a prolonged downturn, of getting products approved.

“Mass firings at the US Food and Drug Administration are particularly risky for small- and mid-cap biotech companies that have innovative treatments in clinical trials but no products on the market to keep them afloat,” it said.

In turn, this has driven a major downturn in investment, seeing biotech companies raising just $4.2bn this year, compared to $11.1bn in the same period last year, according to LSEG data.

Throughout 2023, OCT continued to synthesise new derivatives, and the library now includes close to 500 proprietary compounds. Furthermore, according to its website, OCT has developed ‘a proprietary library of approximately 2,000 compounds’

The potential value of these largely untapped assets is huge, and depending on what happens to the IP post-administration, could represent a game-changing library for a company with the right funding and resources to develop them fully.

Business of Cannabis has been made aware that discussions around the future of this licence, and its associated assets, are still being discussed due to the early stage of the administration process.

Last year, OCT reported that four patent applications had been granted for this IP, and discussions were ongoing with Canopy regarding further patent applications, which would have been co-owned by the two companies.

In 2023, OCT announced that it was moving into oncology having identified a potential ‘first in class’ immunotherapy agent for the treatment of solid tumours, based on an asset which arose from this extensive library.

This would have targeted a market of therapies against solid tumours, it says was projected to be worth US$532bn by 2032. However, due to financial constraints, OCT soon rolled back activity on this programme to focus on its lead compound.

Another major loss

The collapse of OCT represents another significant loss both to the severely underfunded pharmaceutical cannabis sector, and the UK’s biotech sector as a whole.

After a tumultuous few years following its listing on the London Stock Exchange in 2021, OCT appeared to be making meaningful progress under the new leadership of Clarissa Sowemimo-Coker.

Despite clinical progress and meeting its development targets, the company continued to struggle to secure funding as the wider financial environment soured.

In May 2024, Sowemimi-Coker told Business of Cannabis that its decision to exit the public market reflected the wider struggles of biotech and small-cap companies in accessing capital, and the company believed a ‘far larger pool of capital’ would be available from private investors.

Having launched a new major fundraising initiative in March 2025, targeting a £10M raise, the growing caution of investment in the biotech space, thanks largely to uncertainties surrounding the new Trump administration, is likely to have thwarted these efforts.

Contd

As such, Dillistone announced that Pomeroy had informed them that OCTH entered into administration on May 2, 2025.

Furthermore, according to Companies House, OCTH’s address was changed to that of the administrator on May 08, and authenticated by Baker.

What’s next for OCT’s intellectual property?

As a pre-revenue company, not expected to commercialise its leading drug programme until 2028, OCT’s value lies almost entirely in its intellectual property (IP).

However, determining a concrete value for these assets largely depends on who you ask.

As of July 30, 2024, the most recently available company accounts, OCT has several patents in various markets protecting its lead clinical asset, OCT461201.

OCT461201, a small small-molecule new chemical entity (NCE) CB2 agonist, being developed for diabetic peripheral neuropathy (DPN), chemotherapy-induced peripheral neuropathy (CIPN), and irritable bowel syndrome (IBS), was scheduled to begin Phase II clinical trials this year.

Eight patents had been granted for this asset as of July 30, 2024, covering the US, Canada, China, Brazil, Israel, Korea, Mexico, and New Zealand, with another six follow-up applications filed.

OCT estimates that CIPN and IBS together represent commercial opportunities worth over US$5.8bn by 2030

In February 2024, OCT received a reiterated valuation of £25.3m from leading independent research firm Edison, placing its value at over 5x its market cap at the time.

Edison’s valuation was ‘100% ascribed’ to OCT’s leading compound, which Edison expects to launch in 2030. However, it noted that its second compound has significant ‘potential upside’ and plans to incorporate this into its valuation ‘once it enters the clinic’.

According to the latest available data, patents have been filed for its second compound, OCT130401, a phytocannabinoid-based inhalation therapy targeting Trigeminal Neuralgia (TN), but have not yet been granted.

Licensed assets and IP

Back in 2021, OCT announced that it had signed an exclusive worldwide licensing agreement with Canopy Growth Corporation

This gave OCT the exclusive right to their entire pharmaceutical cannabinoid derivative library, including 335 derivatives and intellectual property rights, including 14 patent families and associated research data.

Contd

Https://businessofcannabis.com/oxford-cannabinoid-technologies-collapses-dealing-latest-blow-to-embattled-cannabis-biotech-sector/#:~:text=As%20such%2C%20Dillistone%20announced%20that,08%2C%20and%20authenticated%20by%20Baker.

BYBEN STEVENS

MAY 14, 2025

IN BUSINESS OF CANNABIS EUROPE, COMPANIES, PHARMACEUTICAL

Oxford Cannabinoid Technologies Holdings, one of the UK’s few remaining pharmaceutical cannabis companies, appears to have entered administration.

Like many early-stage biotech companies, OCTH, the holding company of its trading entity Octavian Therapeutics, had always been reliant on investment to push forward its clinical trials.

While there has been no official statement from the company or its administrators, Rushtons Insolvency Limited, numerous public filings confirm they have been appointed.

As such, their promising drug development pipeline, alongside valuable intellectual property for any similar biotech operators, is now likely up for grabs.

Its collapse is reflective of a wider crisis in the global biotech sector, particularly in the US where OCT saw its future, seeing widespread job cuts, a significant slowdown of M&A activity, and public investment opportunities all but grind to a halt.

What happened?

On Friday, May 09, 2025, notice that OCTH had appointed administrators was published in The Gazette, the UK’s official public record of insolvency proceedings.

According to the filing, on May 02, Nicola Baker of Rushtons Insolvency Limited, was appointed as the company’s administrator.

Business of Cannabis has contacted OCT, its communications provider, and the administrators, but as of the date of publication has received no response to our enquiries.

However, a filing from AIM-listed Dillistone Group Plc (DSG), where OCT’s non-executive director and former Chair Julie Pomeroy is also a director, appeared to confirm the administration.

Under Rule 17 and Schedule 2, Paragraph (G) of the AIM Rules for Companies, listed companies must detail any directorships in any other companies held by their directors.

Contd

Just checking in, and interesting that the initial RTO price was 10p, and adjusted for all placings etc, the price would now be around 5.65p. That would match the opening price from 2021. So at 10p would be essentially near double the orginal price, not exactly matching it. So for me the base for this would be around 5.65p and then whatever multiples of that going forward, based on progression.

As for the person who claims to have removed themselves, firstly all posts were deleted from this site, which you cannot do yourself. Have they been banned? I am not sure as they posted on the other site they were leaving, so again I can only assume they have had a knock on the door and threatened with some legal action for the stuff they had been writing and agreed to have the majority of content removed. They fell foul of the rules and the site had to act as its quite possible they were contacted by the company? You don't just rock up after posting at 2am's and 5am's and all day everyday and suddenly say "I have decided to sell up and leave". Its not that easy. The haramzada kuta has got his just reward!

Https://www.thetimes.com/business-money/technology/article/tory-peers-cannabis-medicines-firm-goes-under-xdm5nng00

Cannot get the full article, but it seems they have gone into administration which is a bit of a surprise given the potential and not being able to raise the funds. Hopefully through administration it might find a better route to survival.

Thanks Lovely boy that adds up nicely now. I was using TIKR to source information

There has been a shift to a lot significant nominee holding as being large holders. I can only assume that some of the larger holders have moved across their holdings, otherwise there has been no announcements of sellers. What is also interesting is that 26.6% of all holdings is held in HL nominees ltd, in three seperate significant accounts. There was no previous entry for any HL nominee holdings. HSBC nor Interactive were there previously to my knowledge.

I hope you and especially your wife are able to keep going through this test. Just reading through this and visualising it was tough but you both lived through it. As paname says stay patient focused and know it does get better. After hardship does come ease. I hope also Paname you also get through your long drive to better health, and thank you for sharing your own situation.

TT If you had any morals or a heart you know when to open your mouth or shut it. I hope you have learnt a lesson tonight.

You are telling a lot about yourself my friend. Its understandable that not everyone has the stomach to take on risk, and you have to remember this should be treated as money that can be afforded to be lost, otherwise you should not be invested let alone TRADING IT! It can also be life changing not just for those that will be saved but for those who took the risk and it came off positive. So you will never be able to understand the mindset of long term holders but then resort to prod for what you want to believe, and hope it sticks.

Makabo waived payment of more than 85 per cent of its contracted fees to link remuneration directly to the success of the Company, by accepting 2,464,625 options over new Ordinary Shares (the "Options") with an exercise price of 1.622965p per ordinary share. The Options were granted on a pro-rata monthly basis and will all vest and become exercisable on 25 June 2025 assuming that the VWAP of the Ordinary Shares for the period 25 May 2025 to 24 June 2025 is equal or greater than 3.24593p, being twice or greater than the Options grant price.

*This would mean the contracted fees were £40,000 and this has been waived for a potential £80,000+ down the line. Yep according to TT he must be stupid! We are all stupid! LOL

Well you can pay me when you are ready because as a long termer I am not sick but patient.

Great news and no doubt the beginning of much more over the months.

Https://octavianrx.com/news-and-media/oct-holdings-announces-rebrand-to-octavian-therapeutics-appointment-of-new-chair-and-fundraising-launch

Investing and pumping are two seperates. Invest because you are satisfied that this meets all your research criteria and as a company has minimised risk. 'pumpers' have no affiliation to the stock, not interested in where it is going, happy to live off adrenlin rushes and the stress that goes with it. Technically high level gambling.

Been here for over 5 years, happy with accumulating, especially on days like this, no stress, just sitting in the background now, and saving lives is the goal. Should it be that we benefit from that, then that is secondary but welcomed.

It all comes down to the mindset you approach CIZ with. Investor or Pumper. Long term or Short term. peace or stress.